Insulin degludec/insulin aspart
| Insulin degludec/insulin aspart | |
|---|---|
| INN | |
| Drug class | |
| Routes of administration | Subcutaneous injection |
| Pregnancy category | C |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | Rx-only |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
Insulin degludec/insulin aspart is a combination medication used in the management of diabetes mellitus. It is a mixture of two types of insulin: insulin degludec, a long-acting insulin, and insulin aspart, a rapid-acting insulin. This combination is marketed under the brand name Ryzodeg.
Medical uses[edit]
Insulin degludec/insulin aspart is indicated for the treatment of type 1 diabetes and type 2 diabetes in adults. It helps to control blood glucose levels by providing both basal and prandial insulin coverage.
Mechanism of action[edit]
The combination of insulin degludec and insulin aspart works by mimicking the body's natural pattern of insulin release. Insulin degludec provides a steady, long-lasting insulin level, while insulin aspart offers a rapid onset of action to manage blood sugar spikes after meals.
Administration[edit]
The medication is administered via subcutaneous injection. The dosing schedule is typically individualized based on the patient's needs, blood glucose monitoring results, and glycemic control goals.
Side effects[edit]
Common side effects include hypoglycemia, allergic reactions, and injection site reactions. Patients should be monitored for signs of low blood sugar and other adverse effects.
See also[edit]
References[edit]
